Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Withdrawal Study in Juvenile Idiopathic Arthritis
2017-004518-24Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Baricitinib arm with Placebo arm (2 arms). Primary endpoint: Time to disease flare. Status: unknown.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2017-004518-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004518-24.